PDF(Pubmed)
Abstract：
OBJECTIVE: Small nucleolar RNAs (snoRNAs) form clusters within the genome, representing a mysterious category of small non-coding RNAs. Research has demonstrated that aberrant snoRNAs can contribute to the development of various types of cancers. Recent studies have identified snoRNAs as potentially valuable biomarkers for the diagnosis or/and prognosis of cancers. However, there has been a lack of comprehensive reviews on prognostic and diagnostic snoRNAs across different types of cancers.
METHODS: We conducted a systematic search of various databases including Google Scholar, Medline, Cochrane, Scopus, PubMed, Embase, ScienceDirect, Ovid-Medline, Chinese National Knowledge Infrastructure, WanFang, and SinoMed with a time frame reception to December 30, 2022. A total of 49 relevant articles were included in our analysis, consisting of 21 articles focusing on diagnostic aspects and 41 articles focusing on prognostic aspects. Pooled odds ratio, 95% confidence intervals (CIs), and hazard ratio (HR) were utilized to evaluate clinical parameters and overall survival (OS), respectively.
RESULTS: The findings indicated that area under the curve, sensitivity, and specificity were 0.85, 75%, and 80% in cancer, respectively. There was a possibility that snoRNAs had a positive impact on the diagnosis (risk ratio, RR = 2.95, 95% CI: 2.75-3.16, P = 0.000) and OS (HR = 1) in cancer. Additionally, abnormally expressed snoRNAs were associated with a positive impact on OS time for chronic lymphocytic leukemia (HR: 0.88, 95%Cl: 0.69-1.11, P < 0.00001), colon adenocarcinoma (HR: 0.97, 95%Cl: 0.91-1.03, P < 0.0001), and ovarian cancer (HR: 0.98, 95%Cl: 0.98-0.99, P < 0.00001). However, dysregulated snoRNAs of colon cancer and colorectal cancer had a negative impact on OS time (HR = 3.01 and 1.01 respectively, P < 0.0001).
CONCLUSIONS: The results strongly suggested that snoRNAs could serve as potential novel indicators for prognosis and diagnosis in cancers. This systematic review followed the guidelines of the Transparent Reporting of Systematic Review and Meta-Analyses (PROSPERO register: CRD42020209096).
METHODS: We conducted a systematic search of various databases including Google Scholar, Medline, Cochrane, Scopus, PubMed, Embase, ScienceDirect, Ovid-Medline, Chinese National Knowledge Infrastructure, WanFang, and SinoMed with a time frame reception to December 30, 2022. A total of 49 relevant articles were included in our analysis, consisting of 21 articles focusing on diagnostic aspects and 41 articles focusing on prognostic aspects. Pooled odds ratio, 95% confidence intervals (CIs), and hazard ratio (HR) were utilized to evaluate clinical parameters and overall survival (OS), respectively.
RESULTS: The findings indicated that area under the curve, sensitivity, and specificity were 0.85, 75%, and 80% in cancer, respectively. There was a possibility that snoRNAs had a positive impact on the diagnosis (risk ratio, RR = 2.95, 95% CI: 2.75-3.16, P = 0.000) and OS (HR = 1) in cancer. Additionally, abnormally expressed snoRNAs were associated with a positive impact on OS time for chronic lymphocytic leukemia (HR: 0.88, 95%Cl: 0.69-1.11, P < 0.00001), colon adenocarcinoma (HR: 0.97, 95%Cl: 0.91-1.03, P < 0.0001), and ovarian cancer (HR: 0.98, 95%Cl: 0.98-0.99, P < 0.00001). However, dysregulated snoRNAs of colon cancer and colorectal cancer had a negative impact on OS time (HR = 3.01 and 1.01 respectively, P < 0.0001).
CONCLUSIONS: The results strongly suggested that snoRNAs could serve as potential novel indicators for prognosis and diagnosis in cancers. This systematic review followed the guidelines of the Transparent Reporting of Systematic Review and Meta-Analyses (PROSPERO register: CRD42020209096).
摘要：
目的：小核仁RNA（snoRNA）在基因组中形成簇，代表一类神秘的小型非编码RNA。研究表明，异常snoRNAs可以促进各种类型癌症的发展。最近的研究已经将snoRNA鉴定为用于癌症的诊断或/和预后的潜在有价值的生物标志物。然而,对于不同类型癌症的预后和诊断性snoRNAs缺乏全面的综述.
方法：我们对各种数据库进行了系统的搜索，包括GoogleScholar，Medline,科克伦,Scopus,PubMed,Embase,ScienceDirect,Ovid-Medline,中国国家知识基础设施，万方,和SinoMed，接待时间为2022年12月30日。我们的分析共包括49篇相关文章，由21篇专注于诊断方面的文章和41篇专注于预后方面的文章组成。汇总赔率比，95%置信区间(CI)，和风险比(HR)用于评估临床参数和总生存期(OS)，分别。
结果：研究结果表明，曲线下面积，灵敏度,特异性为0.85，75%，80%的癌症患者，分别。snoRNA有可能对诊断产生积极影响(风险比，RR=2.95，95%CI：2.75-3.16，P=0.000）和OS（HR=1）。此外,snoRNAs异常表达与慢性淋巴细胞白血病OS时间的正向影响相关(HR:0.88,95%Cl:0.69-1.11,P<0.00001),结肠腺癌(HR:0.97,95%Cl:0.91-1.03,P<0.0001),和卵巢癌（HR：0.98，95％Cl：0.98-0.99，P<0.00001）。然而,结肠癌和结直肠癌的snoRNAs失调对OS时间有负面影响(HR=3.01和1.01,P<0.0001)。
结论：结果强烈表明snoRNAs可以作为癌症预后和诊断的潜在新指标。本系统评价遵循系统评价和荟萃分析的透明报告指南（PROSPERO注册：CRD42020209096）。
方法：我们对各种数据库进行了系统的搜索，包括GoogleScholar，Medline,科克伦,Scopus,PubMed,Embase,ScienceDirect,Ovid-Medline,中国国家知识基础设施，万方,和SinoMed，接待时间为2022年12月30日。我们的分析共包括49篇相关文章，由21篇专注于诊断方面的文章和41篇专注于预后方面的文章组成。汇总赔率比，95%置信区间(CI)，和风险比(HR)用于评估临床参数和总生存期(OS)，分别。
结果：研究结果表明，曲线下面积，灵敏度,特异性为0.85，75%，80%的癌症患者，分别。snoRNA有可能对诊断产生积极影响(风险比，RR=2.95，95%CI：2.75-3.16，P=0.000）和OS（HR=1）。此外,snoRNAs异常表达与慢性淋巴细胞白血病OS时间的正向影响相关(HR:0.88,95%Cl:0.69-1.11,P<0.00001),结肠腺癌(HR:0.97,95%Cl:0.91-1.03,P<0.0001),和卵巢癌（HR：0.98，95％Cl：0.98-0.99，P<0.00001）。然而,结肠癌和结直肠癌的snoRNAs失调对OS时间有负面影响(HR=3.01和1.01,P<0.0001)。
结论：结果强烈表明snoRNAs可以作为癌症预后和诊断的潜在新指标。本系统评价遵循系统评价和荟萃分析的透明报告指南（PROSPERO注册：CRD42020209096）。
